London, UK; December 11, 2023 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced the appointment of John Isaac, Ph.D., as Chief Scientific Officer. Previous interim Chief Scientific Officer and AviadoBio co-founder, Professor Chris Shaw, will remain an active member of the leadership team and resume his prior roles as Chief Scientific and Clinical Advisor and Board Observer.
“John has made a significant impact on our research and development team since joining…
Download the My Green Lab 2023 Carbon Impact of Biotech & Pharma report now!
In an informative new blog post - AMSBIO reflects on a selection of the groundbreaking life science and biomedical research undertaken by its customers during 2023. From deciphering the intricacies of cancer progression mechanisms to revolutionising wound care, AMSBIO is delighted to have played a supporting role in these scientific endeavours.
Discover an exciting collaboration led by Dr. Ashley M. Laughney from Weill Cornell Medicine and Dr. Samuel F. Bakhoum from Memorial Sloan Kettering Cancer Center where they investigated the intricate mechanisms through which chromosomal instability…
MHA is excited to announce the appointment of Chris Liu as Partner who will lead our successful Transfer Pricing Team in the International Marketplace.
Chris will lead MHA’s Transfer Pricing Team nationally and globally through the Baker Tilly International network. Chris’s extensive experience includes management of transfer pricing projects for numerous multinational groups in the UK and across Europe and he has deep industry expertise in TMT, Financial Services, Real Estate, Life Sciences, Manufacturing, Infrastructure, Energy and Natural Resources. Chris is a native Mandarin and Cantonese…
Biocair, a global leader in GDP logistics for the pharmaceutical, biotechnology and life sciences sectors, is proud to announce its partnership with Aramex Ireland to expand its presence in the Irish market.
With Biocair's focus on providing the most comprehensive time-sensitive and temperature-controlled logistics services available, and Aramex Ireland’s operations and facilities to deliver life science goods, the partnership is poised to grow an established presence in Ireland for the life science market.
Through this partnership, Biocair and Aramex Ireland will offer a fully…
The companies are working together on next-generation technology in the fast-growing field of synthetic biology. This new technology will improve the quality, speed, and cost of developing synthetic biological solutions such as life-saving vaccines, medicines, treatments, and therapies.
Cambridge, UK, 06 December 2023 – EVONETIX LTD (‘Evonetix’), the company developing semiconductor scale technology to improve access to gene synthesis, today announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc. (ADI), a global semiconductor leader.…
BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures
BioMavericks awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December
Sandwich, UK, 6th December 2023 / Sciad Newswire / Discovery Park / BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £…
ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.
Ambrose Healthcare is seeking to develop new treatments for rare diseases and patients managed in hospitals and specialist care. The company, incorporated in 2022, has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry.
VAL401 is the reformulation of the established…
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822
Submission represents first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver disease
Cambridge, UK, 4 December 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced its PhysioMimix…
Sandwich, Kent, UK, 4th December 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.
DPV was formed in 2022 by Discovery Park to invest in promising, fast-growing life-science companies with close links to the innovation ecosystem at Discovery Park…